Physician profile
David Alonso
NPI 1467403246
$8,817.93
in general payments reported to CMS, 2019-2025
41 companies · $738 in 2025
The $738 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $896 · 2021: $2,232 · 2022: $1,325 · 2023: $1,292 · 2024: $690 · 2025: $738.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,719.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,287.33 | 2019-2025 | Ubrelvy, Linzess, Viberzi |
| Amgen INC. | $1,121.21 | 2019-2025 | Repatha, Otezla, Evenity |
| Astrazeneca Pharmaceuticals LP | $830.16 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $788.37 | 2019-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $749.70 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $633.91 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $507.24 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $444.10 | 2019-2025 | Ofev, Jardiance, Jascayd |
| Daiichi Sankyo INC. | $355.22 | 2019-2023 | Injectafer |
| Amarin Pharma, INC. | $318.78 | 2019-2022 | |
| Exact Sciences Corporation | $227.26 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $179.39 | 2019-2021 | |
| Lilly USA, LLC | $157.40 | 2019-2025 | Mounjaro, Jardiance |
| Idorsia Pharmaceuticals US INC | $151.04 | 2023 | Quviviq |
| Hologic Sales and Service, LLC | $107.84 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Alonso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.